Freedom of Information Request: Our Reference CTMUHB_71_25

You asked:

A. Please provide the number of migraine patients treated in the last 4 months with:

- Atogepant (Aquipta)
- Erenumab (Aimovig)
- Eptinezumab (Vyepti)
- Fremanezumab (Ajovy)
- Galcanezumab (Emgality)
- Rimegepant (Vydura)
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin)

Please find below tables populated with the data that Medicines Management are able to provide in relation to your enquiry.

The data provided for Secondary Care relates to the latest 4 months available which is 1st October 2024 to 31st January 2025 for Secondary Care.

Unfortunately, we are unable to provide Botulinum Toxin data by patient numbers because not all the issues are made to individuals therefore, we have provided Botulinum Toxin information by number of issues.

The data provided for Primary Care and WP10HP's relates the latest 4 months available which is 1st August 24 to 30 November 24. Unfortunately, we are unable to provide this data by number of patients due to the way the information is recorded in the electronic systems.

Secondary Care

Medicine	**Number of Patients**
Atogepant (Aquipta)	9
Erenumab (Aimovig)	8
Eptinezumab (Vyepti)	0
Fremanezumab (Ajovy)	38
Galcanezumab (Emgality)	18
Rimegepant (Vydura)	10

Secondary Care

Product	**Number of Issues**
Botulinum Toxin (i.e., Botox, Dysport, Xeomin)	
BOTULINUM TOXIN TYPE A (BOTOX)	267
BOTULINUM TOXIN TYPE A (DYSPORT)	5

BOTULINUM TOXIN TYPE A (XEOMIN)	23

Secondary Care WP10HP's

Description	Items - Base Period	Qty Prescribed - Base Period
Baricitinib_Tab 4mg	2	196
Atogepant	1	224
Rimegepant 75mg Oral Lyophilisates Sugar Free	4	68

Primary Care

Description	Items - Base Period	Qty Prescribed - Base Period
Rimegepant 75mg Oral Lyophilisates Sugar Free	59	882

B. How many patients have you treated in the last 4 months for acute migraine with:

- **Rimegepant (Vydura)**

Data on issue by indication (acute migraine) is not centrally recorded. The detailed information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

A treatment pause is routinely and actively considered at 12 months, but the decision to actually discontinue is made on a case-by-case basis and not necessarily mandated, depending upon patient characteristics.